JP2008510126A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510126A5
JP2008510126A5 JP2007506605A JP2007506605A JP2008510126A5 JP 2008510126 A5 JP2008510126 A5 JP 2008510126A5 JP 2007506605 A JP2007506605 A JP 2007506605A JP 2007506605 A JP2007506605 A JP 2007506605A JP 2008510126 A5 JP2008510126 A5 JP 2008510126A5
Authority
JP
Japan
Prior art keywords
polypeptide
rhoa
anln
detecting
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007506605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510126A (ja
JP4874234B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2005/014887 external-priority patent/WO2006016697A1/en
Publication of JP2008510126A publication Critical patent/JP2008510126A/ja
Publication of JP2008510126A5 publication Critical patent/JP2008510126A5/ja
Application granted granted Critical
Publication of JP4874234B2 publication Critical patent/JP4874234B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007506605A 2004-08-10 2005-08-09 非小細胞肺癌関連遺伝子ANLN、およびそのRhoAとの相互作用 Expired - Fee Related JP4874234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60056104P 2004-08-10 2004-08-10
US60/600,561 2004-08-10
PCT/JP2005/014887 WO2006016697A1 (en) 2004-08-10 2005-08-09 Non-small cell lung cancer-related gene, anln, and its interactions with rhoa

Publications (3)

Publication Number Publication Date
JP2008510126A JP2008510126A (ja) 2008-04-03
JP2008510126A5 true JP2008510126A5 (cg-RX-API-DMAC7.html) 2008-09-25
JP4874234B2 JP4874234B2 (ja) 2012-02-15

Family

ID=35355888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506605A Expired - Fee Related JP4874234B2 (ja) 2004-08-10 2005-08-09 非小細胞肺癌関連遺伝子ANLN、およびそのRhoAとの相互作用

Country Status (6)

Country Link
US (1) US20090297500A1 (cg-RX-API-DMAC7.html)
EP (1) EP1787122B1 (cg-RX-API-DMAC7.html)
JP (1) JP4874234B2 (cg-RX-API-DMAC7.html)
AT (1) ATE483979T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005024021D1 (cg-RX-API-DMAC7.html)
WO (1) WO2006016697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8060348B2 (en) 2006-08-07 2011-11-15 General Electric Company Systems for analyzing tissue samples
US8131476B2 (en) 2006-08-07 2012-03-06 General Electric Company System and method for co-registering multi-channel images of a tissue micro array
EP2087140A2 (en) * 2006-11-13 2009-08-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
WO2008120812A1 (en) * 2007-03-30 2008-10-09 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
EP2161577A1 (en) * 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN protein
US12680139B2 (en) 2009-01-07 2026-07-14 Myriad Genetics, Inc. Cancer biomarkers
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP5905003B2 (ja) 2010-07-09 2016-04-20 ソマロジック・インコーポレーテッド 肺癌バイオマーカーとその使用
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
US10551378B2 (en) 2011-09-09 2020-02-04 Konica Minolta, Inc. Tissue staining method
BR112014006432B8 (pt) * 2011-10-24 2022-10-25 Somalogic Inc Método in vitro para diagnosticar se um indivíduo tem ou não câncer, método implementado por computador, produto de programa de computador
JP5806168B2 (ja) * 2012-06-19 2015-11-10 国立大学法人 岡山大学 抗浸潤薬の新規スクリーニング法
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10870854B2 (en) 2016-06-09 2020-12-22 The Board Of Regents Of The University Of Texas System Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CA2522299A1 (en) * 2003-04-15 2004-10-28 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods

Similar Documents

Publication Publication Date Title
Edamoto et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis
US10041126B2 (en) Monocyte biomarkers for cancer detection
JP2009519002A5 (cg-RX-API-DMAC7.html)
Khosla et al. miR‐26b‐5p helps in EpCAM+ cancer stem cells maintenance via HSC71/HSPA8 and augments malignant features in HCC
WO2008132155A2 (en) Inhibitors of the binding between hdm2 and the proteasome
JP2012512389A5 (cg-RX-API-DMAC7.html)
CN109337909B (zh) 一种检测肝癌耐药细胞株的核酸适体及其应用
US12325880B2 (en) Identification of PDE3 modulator responsive cancers
JP2008502332A5 (cg-RX-API-DMAC7.html)
CN108866064A (zh) 一种靶向转移性人乳腺癌细胞的核酸适配体及其应用
Wang et al. Classification of osteosarcoma based on immunogenomic profiling
JP2007526759A5 (cg-RX-API-DMAC7.html)
Lan et al. Significance of the detection of TIM-3 and FOXJ1 in prostate cancer
Ojima et al. Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment
Shukla et al. Unbiased peptoid cell screen identifies a peptoid targeting newly appeared cell surface vimentin on tumor transformed early lung cancer cells
CN106676183A (zh) Zfhx4作为食管癌预后诊断的生物标志物
Hui Human hepatocellular carcinoma: expression profiles-based molecular interpretations and clinical applications
Murray et al. Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types
CN112162097B (zh) Gdf1作为评估pd-1单抗治疗效果的生物标志物
CN105203763B (zh) 一种口腔癌特异性检测的试剂盒
CN104039328A (zh) 对蛋白酶体抑制剂的反应的生物标记
JP2007523640A5 (cg-RX-API-DMAC7.html)
Midorikawa et al. Molecular targets for liver cancer therapy: From screening of target genes to clinical trials
CN111944821A (zh) 一种结肠癌核酸适体的组织样本快速筛选及其在检测制剂中的应用
Olivier et al. Prognostic and predictive value of TP53 mutations in human cancer